权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies on Endocrine Therapy for Endometriosis

子宫内膜异位症内分泌治疗的研究

基本信息

批准号：
01480393
负责人：
TERAKAWA Naoki
金额：
$ 2.62万
依托单位：
Tottori University School of Medicine (1990)Osaka University (1989)
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1989
资助国家：
日本
起止时间：
1989 至 1990
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-01480393/
关键词：
Endometriosis Endocrine therapy GnRH agonist Danazol 実験的子宮内膜症

项目摘要

GnRH agonist and danazol are useful for treatment of patients with endometriosis. These compounds induce atrophy and regression of endometriosis, but the action mechanisms are still unclear. The present study, therefore, was undertaken to elucidate the mechanisms of these compounds in the treatment of endometriosis. In addition, a combination therapy with these compounds for endometriosis was also evaluated. With use of experimental endometriosis of female rats, the effects of these compounds were examined. The combination therapy (16/17) was shown to be superior to danazol (9/20) or GnRH agonistalone (14/24) to induce atrophy and regression of fluid in experimental endometriosis. Administration of GnRH agonist decreased serum estradiol level, but use of danazol did not. The findings suggest that a combination therapy of GnRH agonist and danazol, which show different mode of action, may be a potential modelity in treatment of patients with endometriosis.A clinical trial was initiated to examine whether the combination therapy of GnRH agonist and danazol is useful for endometriosis. The combination therapy was more effective to induce atrophy of endometriosis than GnRH agonist or danazol alone. The potential application of combination therapy in the treatment of patients with endometriosis should be evaluated with large scale clinical trials.

GnRH 激动剂和达那唑可用于治疗子宫内膜异位症患者。这些化合物可诱导子宫内膜异位症萎缩和消退，但其作用机制仍不清楚。因此，本研究旨在阐明这些化合物治疗子宫内膜异位症的机制。此外，还评估了这些化合物对子宫内膜异位症的联合疗法。通过使用雌性大鼠的实验性子宫内膜异位症，检查了这些化合物的作用。在诱导实验性子宫内膜异位症中液体萎缩和消退方面，联合疗法 (16/17) 优于达那唑 (9/20) 或 GnRH 激动剂 (14/24)。使用 GnRH 激动剂可降低血清雌二醇水平，但使用达那唑则不会。研究结果表明，GnRH激动剂和达那唑的联合治疗具有不同的作用方式，可能成为治疗子宫内膜异位症患者的潜在模型。我们启动了一项临床试验，以检验GnRH激动剂和达那唑的联合治疗是否对子宫内膜异位症有效。联合治疗比单独使用 GnRH 激动剂或达那唑更能有效诱导子宫内膜异位症萎缩。联合疗法在治疗子宫内膜异位症患者中的潜在应用应通过大规模临床试验进行评估。